Vaxcyte files preliminary prospectus for common stock and pre-funded warrants offering, terms not yet set

Filed October 6, 2026 · ~2 min read

Key Changes

• high

  Vaxcyte is offering common stock and pre-funded warrants, but the number of shares, offering price, and proceeds are left blank in this preliminary prospectus supplement.

  The Offering verify on EDGAR →
• high

  Concurrently, Vaxcyte is offering convertible senior notes due 2032 in a separate offering, with principal amount and interest rate also left blank.

  The Offering verify on EDGAR →
• medium

  The last reported sale price of Vaxcyte common stock on Nasdaq was $73.82 per share on October 5, 2026.

  The Offering verify on EDGAR →